Your search for apixaban returned 48 results

Fewer compliance events seen with apixaban versus enoxaparin for extended-duration VTE prophylaxis after abdominopelvic oncologic surgery

Improved communication with patients about cost, bleeding, and monitoring may increase compliance

The researchers found the risk of GI bleeding was lower for apixaban versus dabigatran or rivaroxaban.

Among new users, rates of recurrent venous thromboembolism, GI and intracranial bleeding lower with apixaban than rivaroxaban

While the use of NSAIDs was low in the ARISTOTLE trial, NSAID users had a higher risk for bleeding than non-users.

Lower rates seen for ischemic stroke or systemic embolism, GI bleeding or intracranial hemorrhage.

Different factor concentrates can reverse some of the alterations in hemostasis attributed to apixaban.

Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic cancer, is safe and well tolerated.

Apixaban is more effective than aspirin in reducing the risk of repeat stroke and systemic embolism in patients with atrial fibrillation (AF) who are unsuitable for vitamin K antagonists (VKA) therapy.

Compared with warfarin, apixaban was correlated with reduced risk of major bleeding and intracranial bleeding (adjusted hazard ratios, 0.66 and 0.4, respectively) and dabigatran was correlated with reduced risk of intracranial bleeding (adjusted hazard ratio, 0.45) among patients with atrial fibrillation.